Good morning,
v\:* {behavior:url(#default#VML);}
o\:* {behavior:url(#default#VML);}
w\:* {behavior:url(#default#VML);}
.shape {behavior:url(#default#VML);}
We promised you another FITX like alert, and here it is…
ITonis, Inc (ITNS)
ITNS closed yesterday at around $0.005, and has pulled backed significantly from former support and 50dma of $0.010.
Now here’s a quick basic technical trading lesson. Typically when a chart has broken support (or broken through resistance) it re-tests that level. If the level holds, it will usually continue the trend. If that level does not hold, it can reverse.
Given this, we expect ITNS to bounce from these levels and move towards its 50 dma / former support of $0.01.
And we are very confident this could happen today.
ITNS is getting a lot of buzz today with many newsletters covering it. We therefore think there could be a strong move up, similar to FITX on Monday.
We also love the small float and cheap market cap on ITNS. Here’s an extract from OTCMarkets.com. As you can see, the tiny float of only 29 million ($145k) means it could really fly with strong volume.
| Market Value |
$4,196,039 |
a/o Mar 27, 2013 |
| Shares Outstanding |
777,044,186 |
a/o Mar 12, 2013 |
| Float |
29,066,067 |
a/o Nov 30, 2011 |
With all these bullish technical indicators, internals and newsletter coverage, its hard not to take a serious look at ITNS today.
A Little Information About ITonis, Inc
(ITNS)…
Itonis, Inc, established in 2005, is an Orange County, California based holding
company currently undergoing a
company-wide transformation to embark upon an aggressive acquisition plan to
purchase high growth entrepreneurial companies that have established
themselves, or are expected to establish themselves as leaders in various
market niches.
The company has relocated its headquarter offices to Orange
County, CA in order to invigorate its operations and to implement company
growth plans. A newly formed executive management team has been put in place,
along with the appointment of a new board of directors. The transition is well
underway.
The incoming management team brings decades of experience as
successful business leaders and entrepreneurs who are dedicated to the planned
vision of acquiring small companies with high growth potential. The executive
team and its board of directors are well positioned to steer the company into a
profitable future and are looking forward to the first of many exciting and
successful years to come.
Normal
0
false
false
false
EN-AU
X-NONE
X-NONE
MicrosoftInternetExplorer4
/* Style Definitions */
table.MsoNormalTable
{mso-style-name:"Table Normal";
mso-tstyle-rowband-size:0;
mso-tstyle-colband-size:0;
mso-style-noshow:yes;
mso-style-priority:99;
mso-style-qformat:yes;
mso-style-parent:"";
mso-padding-alt:0cm 5.4pt 0cm 5.4pt;
mso-para-margin-top:0cm;
mso-para-margin-right:0cm;
mso-para-margin-bottom:10.0pt;
mso-para-margin-left:0cm;
line-height:115%;
mso-pagination:widow-orphan;
font-size:11.0pt;
font-family:"Calibri","sans-serif";
mso-ascii-font-family:Calibri;
mso-ascii-theme-font:minor-latin;
mso-fareast-font-family:"Times New Roman";
mso-fareast-theme-font:minor-fareast;
mso-hansi-font-family:Calibri;
mso-hansi-theme-font:minor-latin;
mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:minor-bidi;}
ITonis Pharmaceuticals
Itonis pharmaceuticals was created as a new division of Itonis, Inc. in
collaboration with world-famous Dr. Charles Hensley, the inventor of the Zicam®
Cold Remedy. This innovative pharmaceutical organization will produce and
market prescription homeopathic preparations and over-the-counter products to
treat chronic diseases and common ailments. The company will select products
based on the speed to market seeking to bypass where appropriate the
traditional and lengthy FDA approval process, while still maintaining the
strictest levels of both safety and efficacy.
Dr. Hensley is a pioneer in the development and marketing of safe and
effective therapeutic nutraceutical and homeopathic preparations. He was a
founder of Geltech, LLC, the company that launched the Zicam® Cold Remedy,
making the product a household name and forever changing the marketing and
product placement paradigm for homeopathic drugs in the United States. Dr.
Hensley and his team plan to use the same methodologies to revolutionize the
treatment of several other common ailments and other chronic diseases.
Recent News
- Itonis Pharmaceuticals Update on Its Upcoming Anti-Nausea Product
- Charles
Hensley, Ph.D., Inventor of Zicam(R) Cold Remedy, and Itonis
Pharmaceuticals Announce Relocation to Larger Office Facilities
- Charles
Hensley, Ph.D., Inventor of Zicam(R) Cold Remedy, and Itonis
Pharmaceuticals, Readying Manufacturer for Anti-Nausea Nasal Spray
- Charles
Hensley, Ph.D., Inventor of Zicam(R) Cold Remedy, and Itonis
Pharmaceuticals, Begin Organizing Case Studies on Anti-Nausea Product
- Goldman Small Cap Research Issues Research Report on Itonis, Inc.
- Charles Hensley, Ph.D., and Itonis Pharmaceuticals Announce Anti-HIV Compound Targeting the Viral Entry Step
- Charles Hensley, Ph.D., Inventor of Zicam(R) Cold Remedy, Creates Itonis Pharmaceuticals, Prepares to Announce Clinical Trial
You can read more about the Company, their world class
management team and the Company’s three subsidiaries, Paramount Discoveries,
App Rocket & ITonis Pharmaceuticals on their website http://itonisholdings.com/
We think ITNS is going to be very big today. We think with the combination of technical analysis, a lot of newsletter buzz and the possibility of news hitting the wires, ITNS could give us FITX type gains.
We urge you put ITNS on your radar today. As always, the best of luck, stick to your rules, lock in
gains, and most of all, have some fun.
Normal
0
false
false
false
EN-AU
X-NONE
X-NONE
MicrosoftInternetExplorer4
/* Style Definitions */
table.MsoNormalTable
{mso-style-name:"Table Normal";
mso-tstyle-rowband-size:0;
mso-tstyle-colband-size:0;
mso-style-noshow:yes;
mso-style-priority:99;
mso-style-qformat:yes;
mso-style-parent:"";
mso-padding-alt:0cm 5.4pt 0cm 5.4pt;
mso-para-margin:0cm;
mso-para-margin-bottom:.0001pt;
mso-pagination:widow-orphan;
font-size:11.0pt;
font-family:"Calibri","sans-serif";
mso-ascii-font-family:Calibri;
mso-ascii-theme-font:minor-latin;
mso-fareast-font-family:"Times New Roman";
mso-fareast-theme-font:minor-fareast;
mso-hansi-font-family:Calibri;
mso-hansi-theme-font:minor-latin;
mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:minor-bidi;}
The Team
Penny Stock General
Click Below to Join Our Social Media Networks
|
|
Normal
0
false
false
false
EN-AU
X-NONE
X-NONE
————————————————————————————- DISCLAIMER —————————————————————————————
Never invest in any stock featured on our site or emails unless you can afford
to lose your entire investment.
Full disclaimer can be read at
http://www.pennystockgeneral.com/disclaimer.html
Pennystockgeneral.com employees are not registered as an Investment Adviser in
any jurisdiction whatsoever.
The disclaimer is to be read and fully understood before using our site, or
joining our email list.
None of the materials or advertisements herein constitute offers or
solicitations to purchase or sell securities of the companies profiled herein
and any decision to invest in any such company or other financial decisions
should not be made based upon the information provide herein. Instead pennystockgeneral.com strongly urges
you conduct a complete and independent investigation of the respective
companies and consideration of all pertinent risks. Pennystockgeneral.com does not offer such advice or analysis, and pennystockgeneral.com further urges
you to consult your own independent tax, business, financial and investment
advisors. Investing in micro-cap and growth securities is highly speculative
and carries and extremely high degree of risk. It is possible that an
investor’s investment may be lost or impaired due to the speculative nature of
the companies profiled.
Any statements that express or involve discussions with respect to predictions,
expectations, beliefs, plans, projections, objectives, goals, assumptions or
future events or performance are not statements of historical fact may be
"forward looking statements". Forward looking statements are based on
expectations, estimates, and projections at the time the statements are made
that involve a number of risks and uncertainties which could cause actual
results or events to differ materially from those presently anticipated.
Forward looking statements in this action may be identified through use of
words such as "projects", "foresee", "expects",
"will", "anticipates", "estimates",
"believes", "understands", or that by statements indicating
certain actions "may", "could", or "might" occur.
Understand there is no guarantee past performance will be indicative of future
results.
In preparing this publication, pennystockgeneral.com
has relied upon information supplied by its customers, and press releases which
it believes to be reliable; however, such reliability cannot be guaranteed.
Investors should not rely on the information contained in this website. Rather,
investors should use the information contained in this website as a starting
point for doing additional independent research on the featured companies. The
advertisements in this website are believed to be reliable, however, pennystockgeneral.com and its owners,
affiliates, subsidiaries, officers, directors, representatives and agents
disclaim any liability as to the completeness or accuracy of the information
contained in any advertisement and for any omissions of materials facts from
such advertisement. Pennystockgeneral.com
is not responsible for any claims made by the companies advertised herein.
Pennystockgeneral.com may
receive compensation and its employees and affiliates may own stock that they
have purchased in the open market either prior, during, or after the release of
the companies profile which is an inherent conflict of interest in pennystockgeneral.com statements and
opinions and such statements and opinions cannot be considered independent. Pennystockgeneral.com and its
management may benefit from any increase in the share price of the profiled
companies and hold the right to sell the shares bought at any given time
including shortly after the release of the companies profile. PSG has been compensated up to three thousand dollars for this one day profile of ITNS by a non-affiliated third party MicroCap Consultants.
Pennystockgeneral.com
may on occasion accept compensation in free-trading shares for it’s marketing
services of the company being profiled, and the third party that might have
compensated pennystockgeneral.com
may hold free-trading shares of the company being profiled and could very well
be selling shares of the companies stock at the same time the profile is being
disseminated to potential investors; this should be viewed as a definite
conflict of interest and as such, the reader should take this into
consideration. If Pennystockgeneral.com
ever accepts compensation in the form of free trading shares of the company
being profiled and decides to sell these shares into the public market at any
time before, during, or after the release of the companies profile our
disclaimer will be updated accordingly reflecting the current position of those
free trading shares received as compensation for our services.
/* Style Definitions */
table.MsoNormalTable
{mso-style-name:"Table Normal";
mso-tstyle-rowband-size:0;
mso-tstyle-colband-size:0;
mso-style-noshow:yes;
mso-style-priority:99;
mso-style-qformat:yes;
mso-style-parent:"";
mso-padding-alt:0cm 5.4pt 0cm 5.4pt;
mso-para-margin-top:0cm;
mso-para-margin-right:0cm;
mso-para-margin-bottom:10.0pt;
mso-para-margin-left:0cm;
line-height:115%;
mso-pagination:widow-orphan;
font-size:11.0pt;
font-family:"Calibri","sans-serif";
mso-ascii-font-family:Calibri;
mso-ascii-theme-font:minor-latin;
mso-fareast-font-family:"Times New Roman";
mso-fareast-theme-font:minor-fareast;
mso-hansi-font-family:Calibri;
mso-hansi-theme-font:minor-latin;
mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:minor-bidi;} |
